你可能會喜歡
All the major risk stratification models for myeloma, MGUS, SMM, WM, amyloid in one place! Open Access! @LeukemiaJnl @ZanwarSaurabh nature.com/articles/s4137…
Treatment algorithm for frontline Ph-positive B- cell ALL onlinelibrary.wiley.com/doi/10.1002/aj… #leusm #ALL
✨ IgG4-Related Disease: Emerging Insights One of the best #IgG4RD articles I’ve come across! Published in Allergy (2025) 🧾 🔹 4 Clinical Phenotypes Pancreato-biliary | Retroperitoneal/Aortitis | Head & Neck | Mikulicz/Systemic 🔹 Key Biomarkers Plasmablasts, galectin-3, CCL18…
Just out in the New England Journal of Medicine! Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM nejm.org/doi/full/10.10… 5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and…
Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma ashpublications.org/blood/article/…
The tumultuous development of venetoclax in t(11;14) multiple myeloma Just out in @JCO_ASCO Preview below 👇🏻 ascopubs.org/doi/10.1200/JC… @MyMKaiser @OncoAlert
1/ New @BloodAdvances treasure trove of 🇩🇪 🇺🇸 data about bridging before CAR-T in #MMsm. Bigger is not better when it comes to bridging using chemotherapy... Worse post-CAR-T efficacy (unsurprising: tumor biology as confounder) but also clearly worse cytopenias & infections!
How I treat acute lymphoblastic leukemia in the era of immunotherapy while revisiting the myth of second remission ow.ly/VNYF50WBFRq #HowITreat #lymphoidneoplasia #transplantation
1/ As @End_myeloma has said so eloquently: "The only place where BCMA must come before GPRC5D is the dictionary." Talquetamab bridging before BCMA CAR-T in myeloma - short, very effective, and rapidly becoming my preferred approach for patients with aggressive #MMsm biology!
🎉Finally out🎉 Talquetamab bridging is feasible, safe and effective allowing rapid disease control with minimal grade toxicity @BloodPortfolio ashpublications.org/blood/article-… #mmsm
🧵 How I treat platelet transfusion refractoriness 🩸 Blood 2025 review by Nahirniak et al. 1️⃣ Definition: PR = inadequate post-transfusion platelet increment (PI ≤ 5–10×10⁹/L) on 2 occasions. 📊 CCI = (PI × BSA) / platelet dose. 2️⃣ Causes: 🔹 Immune (HLA antibodies – class I…
Early methionine availability attenuates T cell exhaustion @NatImmunol nature.com/articles/s4159…
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis @LeukemiaJnl nature.com/articles/s4137…
Finally. We have European regulatory approval for high risk smoldering myeloma! Await FDA decision. AQUILA trial. @NEJM Darzalex (Daratumumab)
Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access fees so you can download and read freely! Lots of Tables. Bookmark. @ZanwarSaurabh @myelomaMD @LeukemiaJnl Link: nature.com/articles/s4137…
Reducing Pyrrhic Victories in Allogeneic Stem Cell Transplantation Posttransplantation cyclophosphamide significantly reduced graft-versus-host disease and improved survival in patients undergoing transplantation from a matched related donor. jwat.ch/3GIpaSk @NEJM
🧬 𝗝𝗼𝗶𝗻 𝘂𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 @TheIACH 𝗣𝗼𝘀𝘁-𝗔𝗦𝗖𝗢/𝗘𝗛𝗔 𝟮𝟬𝟮𝟱 𝘄𝗲𝗯𝗶𝗻𝗮𝗿: 𝗦𝘂𝗺𝗺𝗮𝗿𝗶𝘇𝗶𝗻𝗴 𝗠𝗗𝗦 𝗮𝗻𝗱 𝗔𝗠𝗟 𝗱𝗮𝘁𝗮 𝗳𝗿𝗼𝗺 𝗘𝗛𝗔 𝗮𝗻𝗱 𝗔𝗦𝗖𝗢 🗣️ 𝘗𝘳𝘦𝘴𝘦𝘯𝘵𝘦𝘥 𝘣𝘺 𝘈𝘮𝘦𝘳 𝘡𝘦𝘪𝘥𝘢𝘯 🗓️ 𝘛𝘩𝘶𝘳𝘴𝘥𝘢𝘺, 𝘑𝘶𝘭𝘺 24, 2025 🕕…
Bispecific antibodies in diffuse large B-cell lymphoma: a new review. haematologica.org/article/view/1…
United States 趨勢
- 1. Thanksgiving 1.67M posts
- 2. Chiefs 90.7K posts
- 3. Chiefs 90.7K posts
- 4. Lamar 19K posts
- 5. Bengals 23.7K posts
- 6. Bengals 23.7K posts
- 7. Mahomes 28.6K posts
- 8. Zac Taylor 1,377 posts
- 9. Pickens 28K posts
- 10. Sarah Beckstrom 135K posts
- 11. #AEWCollision 6,205 posts
- 12. Joe Burrow 8,790 posts
- 13. Tinsley N/A
- 14. McDuffie 6,872 posts
- 15. Post Malone 5,007 posts
- 16. Isaiah Likely N/A
- 17. Tony Romo 3,321 posts
- 18. #KCvsDAL 9,398 posts
- 19. Jordan Battle N/A
- 20. Chase Brown 1,791 posts
Something went wrong.
Something went wrong.